Novartis manufactures Lucentis [1]. The drug is also known by its generic name, ranibizumab [2].
What is Lucentis used for?
Lucentis is an eye medicine used to treat several eye conditions, including neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) [1][2]. It is also used for myopic choroidal neovascularization (mCNV) [1].
How does Lucentis work?
Lucentis is a vascular endothelial growth factor (VEGF) inhibitor. It works by blocking the action of VEGF, a protein that stimulates abnormal blood vessel growth and leakage in the eye, which can lead to vision loss [2][3].
When does the patent for Lucentis expire?
Information regarding the specific patent expiration dates for Lucentis can be found on DrugPatentWatch.com [4].
Are there other treatments for age-related macular degeneration?
Yes, besides Lucentis, other treatments are available for age-related macular degeneration. These include Eylea (aflibercept), Beovu (brolucizumab), and Avastin (bevacizumab), though Avastin is often used off-label for AMD [5].
Who are Novartis's competitors for AMD treatments?
Key competitors in the age-related macular degeneration treatment market include Regeneron Pharmaceuticals, the maker of Eylea, and Roche and Genentech, who produce Beovu and Avastin [5].
What are the potential side effects of Lucentis?
Common side effects of Lucentis can include eye inflammation, increased intraocular pressure, and visual disturbances. More serious but less common side effects may involve vision loss or changes, and very rarely, events like stroke or heart attack [2][3].
Can biosimilars of Lucentis be developed?
The development and approval of biosimilars for Lucentis are subject to regulatory pathways and patent protections. Biosimilars are intended to be highly similar to the reference biologic drug, offering a potentially lower-cost alternative [4].
Sources:
[1] https://www.gene.com/medicines/lucentis
[2] https://www.drugs.com/lucentis.html
[3] https://www.rxlist.com/lucentis-drug.htm
[4] https://www.drugpatentwatch.com/
[5] https://www.aao.org/eye-health/treatments/amd-treatments